Literature DB >> 9699727

Aberrant neutrophil trafficking and metabolic oscillations in severe pyoderma gangrenosum.

Y Adachi1, A L Kindzelskii, G Cookingham, S Shaya, E C Moore, R F Todd, H R Petty.   

Abstract

Having previously associated metabolic oscillations with cell locomotion, we hypothesized that patients with abnormalities in neutrophil trafficking may display aberrant intracellular oscillations. A pyoderma gangrenosum patient exhibiting aberrant leukocyte trafficking in vivo and skin ulceration without infection was identified. This patient's neutrophils constitutively overexpressed and clustered the leukocyte integrins CR3 and CR4 and failed to display appropriate integrin-to-GPI receptor interactions. Increased levels of tyrosine phosphorylation were observed. NAD(P)H oscillations, which are sinusoidal in normals, were chaotic with multiple frequency components in this patient's neutrophils. Normal cell shape and sinusoidal NAD(P)H oscillations were restored by providing a pulsed electric field to drive metabolic oscillations and by temperature reduction. N-acetyl-D-glucosamine disrupted CR3 clusters and sinusoidal NAD(P)H oscillations returned. Anecdotal reports suggest that local hypothermia is clinically useful for this patient. These data define the first metabolic oscillation-associated disease and suggest that pyoderma gangrenosum can be classified as a dynamical disease at the cellular level.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9699727     DOI: 10.1046/j.1523-1747.1998.00311.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  31 in total

1.  Dissipative metabolic patterns respond during neutrophil transmembrane signaling.

Authors:  H R Petty; A L Kindzelskii
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-06       Impact factor: 11.205

Review 2.  Neutrophil oscillations: temporal and spatiotemporal aspects of cell behavior.

Authors:  H R Petty
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

3.  [Surgical management of Pyoderma gangrenosum].

Authors:  I Sick; B Trautner; T Ruzicka
Journal:  Hautarzt       Date:  2012-07       Impact factor: 0.751

4.  Leukocyte adhesion deficiency-I with a novel intronic mutation presenting with pyoderma gangrenosum- like lesions.

Authors:  Manisha Madkaikar; Khushnooma Italia; Maya Gupta; Mukesh Desai; Amita Aggarwal; Surjit Singh; Deepti Suri; Anju Mishra; Sushant Chavan; Kanjaksha Ghosh; Rishu Sarangal; Sunil Dogra
Journal:  J Clin Immunol       Date:  2015-04-16       Impact factor: 8.317

5.  Successful treatment of pyoderma gangrenosum associated with juvenile idiopathic arthritis with a combination of topical tacrolimus and oral prednisolone.

Authors:  Pradeep Kumar Shenoy Chandrasekhara; Nambiar Veettil Jayachandran; Joe Thomas; Sumeet Agrawal; Gumdal Narsimulu
Journal:  Clin Rheumatol       Date:  2009-02-03       Impact factor: 2.980

Review 6.  [Pyoderma gangrenosum and Sweet's syndrome : Cutaneous manifestations of autoinflammatory disorders].

Authors:  B Meier; J-T Maul; L E French
Journal:  Hautarzt       Date:  2016-12       Impact factor: 0.751

7.  Disseminated refractory pyoderma gangraenosum during an ulcerative colitis flare. Treatment with infliximab.

Authors:  Vasiliki A Zampeli; Undine Lippert; Georgios Nikolakis; Evgenia Makrantonaki; Thrasivoulos G Tzellos; Ulf Krause; Christos C Zouboulis
Journal:  J Dermatol Case Rep       Date:  2015-09-30

Review 8.  [Pyoderma gangrenosum].

Authors:  K Herberger
Journal:  Hautarzt       Date:  2016-09       Impact factor: 0.751

9.  Treatment of pyoderma gangrenosum with infliximab in Crohn's disease.

Authors:  Mark S Sapienza; Sidney Cohen; Anthony J Dimarino
Journal:  Dig Dis Sci       Date:  2004-09       Impact factor: 3.199

10.  Unusual cause of breast wound: postoperative pyoderma gangrenosum.

Authors:  Bahareh Abtahi-Naeini; Fahimeh Bagheri; Mohsen Pourazizi; Mohammad Forozeshfard; Ali Saffaei
Journal:  Int Wound J       Date:  2016-07-21       Impact factor: 3.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.